Cited in:


This article has been cited by:

  1. 1
    N. A. Limdi, T. M. Brown, Q. Yan, J. L. Thigpen, A. Shendre, N. Liu, C. E. Hill, D. K. Arnett, T. M. Beasley, Race influences warfarin dose changes associated with genetic factors, Blood, 2015, 126, 4, 539


  2. You have free access to this content2
    S. E. Kimmel, Warfarin pharmacogenomics: current best evidence, Journal of Thrombosis and Haemostasis, 2015, 13,
  3. 3
    Mariana R. Botton, Patrícia P. Viola, Eliane Bandinelli, Tiago L. L. Leiria, Luis E. P. Rohde, Mara H. Hutz, A New Algorithm for Weekly Phenprocoumon Dose Variation in a Southern Brazilian Population: Role for CYP2C9, CYP3A4/5 and VKORC1 Genes Polymorphisms, Basic & Clinical Pharmacology & Toxicology, 2014, 114, 4
  4. 4
    R M Turner, M Pirmohamed, Cardiovascular Pharmacogenomics: Expectations and Practical Benefits, Clinical Pharmacology & Therapeutics, 2014, 95, 3
  5. 5
    Aparna Chhibber, Deanna L Kroetz, Kelan G Tantisira, Michael McGeachie, Cheng Cheng, Robert Plenge, Eli Stahl, Wolfgang Sadee, Marylyn D Ritchie, Sarah A Pendergrass, Genomic architecture of pharmacological efficacy and adverse events, Pharmacogenomics, 2014, 15, 16, 2025


  6. 6
    Adebowale Adeyemo, Charles Rotimi, What does genomic medicine mean for diverse populations?, Molecular Genetics & Genomic Medicine, 2014, 2, 1